Valeant Pharmaceuticals International (NYSE:VRX) : 12 investment research analysts covering Valeant Pharmaceuticals International (NYSE:VRX) have an average price target of $39.75 for the near short term. The highest target price given by the Brokerage Firm to the stock is $90 and the lowest target is $11 for the short term. Analysts expect the variance to be within $19.53 of the average price.
Valeant Pharmaceuticals International, Inc. has lost 9.48% in the last five trading days and dropped 32.39% in the last 4 weeks. Valeant Pharmaceuticals International, Inc. has dropped 28.33% during the last 3-month period . Year-to-Date the stock performance stands at -80.19%. Also, JP Morgan downgrades its rating on Valeant Pharmaceuticals International (NYSE:VRX). The global brokerage major lowers the current price target from $50 per share to $35 per share. Analysts at the JP Morgan have a current rating of Neutral on the shares. The shares were previously rated Overweight. The rating by the firm was issued on June 23, 2016.
Valeant Pharmaceuticals International (NYSE:VRX) has an average broker rating of 2.87, which is interpreted as a Hold, as rated by 15 equity analysts. Nonetheless, 4 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 8 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 5, which is also a Strong Sell. 3 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $20.01 on Thursday but the bulls could not build on the opening and the stock topped out at $20.46 for the day. The stock traded down to $19.45 during the day, due to lack of any buying support eventually closed down at $20.14 with a loss of -0.64% for the day. The stock had closed at $20.27 on the previous day. The total traded volume was 14,170,047 shares.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Valeant Pharmaceuticals International, Inc., Papa Joseph C had purchased shares worth of $4,944,960 in a transaction dated on June 10, 2016. A total of 202,000 shares were purchased at a price of $24.48 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.